EZH2: a pleiotropic protein.

作者信息

Burmeister Thomas

机构信息

CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN.

出版信息

Blood. 2016 Aug 18;128(7):888-9. doi: 10.1182/blood-2016-06-723916.

DOI:10.1182/blood-2016-06-723916

PMID:27539996

Abstract

摘要

相似文献

EZH2: a pleiotropic protein.

Blood. 2016 Aug 18;128(7):888-9. doi: 10.1182/blood-2016-06-723916.

Histone deacetylase inhibitors deplete enhancer of zeste 2 and associated polycomb repressive complex 2 proteins in human acute leukemia cells.

Mol Cancer Ther. 2006 Dec;5(12):3096-104. doi: 10.1158/1535-7163.MCT-06-0418.

Over-expression of polycomb group protein EZH2 relates to decreased expression of p16 INK4a in cholangiocarcinogenesis in hepatolithiasis.

J Pathol. 2008 Jun;215(2):175-83. doi: 10.1002/path.2345.

Polycomb-group oncogenes EZH2, BMI1, and RING1 are overexpressed in prostate cancer with adverse pathologic and clinical features.

Eur Urol. 2007 Aug;52(2):455-63. doi: 10.1016/j.eururo.2006.11.020. Epub 2006 Nov 17.

Developmental regulation of Suz 12 localization.

Chromosoma. 2005 Aug;114(3):183-92. doi: 10.1007/s00412-005-0008-6. Epub 2005 Jun 29.

Essential role for activation of the Polycomb group (PcG) protein chromatin silencing pathway in metastatic prostate cancer.

Cell Cycle. 2006 Aug;5(16):1886-901. doi: 10.4161/cc.5.16.3222. Epub 2006 Aug 15.

Expression changes in EZH2, but not in BMI-1, SIRT1, DNMT1 or DNMT3B are associated with DNA methylation changes in prostate cancer.

Cancer Biol Ther. 2007 Sep;6(9):1403-12. doi: 10.4161/cbt.6.9.4542.

FOXC1, a target of polycomb, inhibits metastasis of breast cancer cells.

Breast Cancer Res Treat. 2012 Jan;131(1):65-73. doi: 10.1007/s10549-011-1396-3. Epub 2011 Apr 5.

Consequences of the depletion of zygotic and embryonic enhancer of zeste 2 during preimplantation mouse development.

Development. 2003 Sep;130(18):4235-48. doi: 10.1242/dev.00625.

Suz12 is essential for mouse development and for EZH2 histone methyltransferase activity.

EMBO J. 2004 Oct 13;23(20):4061-71. doi: 10.1038/sj.emboj.7600402. Epub 2004 Sep 23.

引用本文的文献

SMARCB1 (INI-1)-Deficient Sinonasal Carcinoma: A Systematic Review and Pooled Analysis of Treatment Outcomes.

Cancers (Basel). 2022 Jul 5;14(13):3285. doi: 10.3390/cancers14133285.

Epigenetic Alterations in Immune Cells of Systemic Lupus Erythematosus and Therapeutic Implications.

Cells. 2022 Feb 1;11(3):506. doi: 10.3390/cells11030506.

Ezh2-mediated epigenetic modification is required for allogeneic T cell-induced lupus disease.

Arthritis Res Ther. 2020 Jun 5;22(1):133. doi: 10.1186/s13075-020-02225-9.

INI-1 (SMARCB1)-Deficient Undifferentiated Sinonasal Carcinoma: Novel Paradigm of Molecular Testing in the Diagnosis and Management of Sinonasal Malignancies.

Oncologist. 2020 Sep;25(9):738-744. doi: 10.1634/theoncologist.2019-0830. Epub 2020 Jun 12.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

Suppr
超能文献

EZH2: a pleiotropic protein.

作者信息

机构信息

出版信息

相似文献

引用本文的文献

文献AI研究员

用中文搜PubMed

文档翻译

Suppr 超能文献

相似文献

引用本文的文献

Suppr超能文献

EZH2: a pleiotropic protein.

作者信息

机构信息

出版信息

相似文献

引用本文的文献

文献AI研究员

用中文搜PubMed

文档翻译

Suppr 超能文献

相似文献

引用本文的文献

Suppr
超能文献